Entrada Therapeutics Inc
NASDAQ:TRDA
Earnings Announcements
Entrada Therapeutics Reports First Quarter 2022 Financial Results
Published: 05/12/2022 11:16 GMT
Entrada Therapeutics Inc (TRDA) - Entrada Therapeutics Reports First Quarter 2022 Financial Results.
Entrada Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities Were $263.9 Million As of March 31, 2022.
Entrada Therapeutics Inc - Qtrly Loss per Share $0.69.
Entrada Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities Were $263.9 Million As of March 31, 2022.
Entrada Therapeutics Inc - Qtrly Loss per Share $0.69.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.73
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.75
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.73
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.75
More details on our Analysts Page.